Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 17/20 | 0.75 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.61 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.61 |
| ▸ | PREP | P48147 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5077374 | 0.88 | DPP4 (0.75) | DPP4DPP7DPP8PREP | |
| SCHEMBL6595949 | 0.86 | DPP4 (1.00) | DPP4DPP7DPP8 | |
| SCHEMBL6596978 | 0.84 | DPP4 (1.00) | DPP4DPP7DPP8 | |
| SCHEMBL6599675 | 0.84 | DPP4 (0.72) | DPP4DPP7DPP8 | |
| SCHEMBL7335876 | 0.84 | DPP4 (0.62) | DPP4DPP7DPP8 | |
| SCHEMBL7335885 | 0.84 | DPP4 (0.62) | DPP4DPP7DPP8 | |
| SCHEMBL1614514 | 0.84 | DPP4 (1.00) | DPP4DPP7DPP8 | |
| SCHEMBL4966643 | 0.84 | DPP4 (1.00) | DPP4DPP7DPP8 | |
| SCHEMBL665511 | 0.83 | DPP4 (0.68) | DPP4DPP7DPP8PREP | |
| Hydrochloric Acid SCHEMBL6704347 | 0.82 | DPP4 (0.68) | DPP4DPP7DPP8PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152745-A1 | Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors | GUILFORD PHARMACEUTICALS, INC. | 2004-08-05 | — | — | US | disclosed |
| US-6124305-A | TREATING NON-INSULIN DEPENDENT DIABETES MELLITUS | NOVARTIS AG (CH) | 2000-09-26 | — | — | US | disclosed |
| US-6011155-A | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV | NOVARTIS AG (CH) | 2000-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152745-A1 | Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors | DPP3, DPP4, DNPEP | DPP4 2/4885DPP7 4/4885DPP8 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.